12:00 AM
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Invokana canagliflozin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 10-5 to recommend approval of diabetes product Invokana canagliflozin from Johnson & Johnson. Four of the panel members who voted against approval said their main concern was approval for a broad indication, as they...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >